Zenicor Medical Systems AB, a leader in medtech solutions for arrhythmia diagnostics, has announced a rights issue of 15.7 MSEK. Scheduled to commence on October 28, 2025, the rights issue offers existing shareholders the opportunity to subscribe for new shares at a price of 1.50 SEK per share, a significant discount to the current market valuation.

The rights issue is structured to allow shareholders on the record date of October 24, 2025, to subscribe for three new shares for every four existing shares they hold. This strategic move is aimed at raising capital to ensure sufficient working capital for organic growth and to rebalance the company's capital structure, including debt amortization.

With commitments from existing shareholders and external investors covering approximately 75% of the total issuance, Zenicor is poised to secure around 11.8 MSEK. This funding is deemed sufficient to cover the company's operational needs for at least the next 12 months, even in a scenario with no revenue growth.

Zenicor's CEO, Mats Palerius, expressed gratitude for the support from existing and new investors, highlighting the company's robust product portfolio and steady revenue growth. The funds raised will enable Zenicor to pursue further growth opportunities, particularly in Sweden and Finland, where the company has a strong pipeline of tenders.

Considering Zenicor's strategic focus and financial position, investors are advised to hold their shares. The company's long-term growth prospects, supported by a solid pipeline and strategic partnerships, present a promising outlook.